Sugi Predict

Sugi Predict / Compounds / SCHEMBL5484210

SCHEMBL5484210

SCHEMBL5484210

OCC1(c2ccc(F)cc2)CCC(NC2CC2)CC1

nearest known ligand 0.41

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 4/20 0.41
▸ SLC6A3 Q01959 3/20 0.41
▸ HSD11B1 P28845 4/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ TACR1 P25103 2/20 0.39
▸ SLC6A2 P23975 1/20 0.37
▸ CACNA1G O43497 4/20 0.36
▸ RORC P51449 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11920268 1.00 SLC6A4 (0.41) SLC6A4SLC6A3HSD11B1ALDH1A1TACR1
SCHEMBL5484212 1.00 SLC6A4 (0.41) SLC6A4SLC6A3HSD11B1ALDH1A1TACR1
SCHEMBL11920687 0.83 SLC6A4 (0.49) SLC6A4HSD11B1TACR1LMNA
SCHEMBL14341347 0.83 SLC6A4 (0.49) SLC6A4HSD11B1TACR1LMNA
SCHEMBL7704791 0.80 SLC6A3 (0.52) SLC6A4SLC6A3HSD11B1SLC6A2
SCHEMBL14341380 0.78 TRPA1 (0.35) SLC6A4HSD11B1TACR1LMNA
SCHEMBL11920605 0.78 TRPA1 (0.35) SLC6A4HSD11B1TACR1LMNA
SCHEMBL11920868 0.78 SLC6A4 (0.36) SLC6A4SLC6A3HSD11B1ALDH1A1TACR1
SCHEMBL5476385 0.78 HSD11B1 (0.51) SLC6A4SLC6A3HSD11B1ALDH1A1TACR1
SCHEMBL11920965 0.78 HSD11B1 (0.51) SLC6A4SLC6A3HSD11B1ALDH1A1TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8772296-B2 Benzamide derivatives and uses related thereto AMGEN INC. (US) 2014-07-08 — — US disclosed
EP-2044004-B1 BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY AMGEN INC (US) 2012-08-15 — — EP disclosed
US-20070299080-A1 N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy AMGEN INC. 2007-12-27 — — US disclosed
US-20070299080-A1 N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy AMGEN INC. 2007-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299080-A1 N-Benzyl-N-methyl-4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzamide; modulating activity of hydroxysteroid dehydrogenases (HSDs), 11 beta-hydroxysteroid dehydrogenases,(also; 17 beta-, 20 alpha-, and 3 alpha-); antidiabetic agents;, obesity, glaucoma, osteoporosis, cognitive disorders; immunotherapy HSD3B1, HSD17B1, HSD3B2 SLC6A4 4417/4885SLC6A3 4307/4885HSD11B1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.